Maverick Simulation Solutions: Strategic Capital Raise and Founder-Led Acquisition
Maverick Simulation Solutions, a Delhi-based innovator in medical simulation, is orchestrating a significant financial maneuver: a ₹125 crore capital raise at ₹3,118 per share, coupled with the acquisition of Voxel-Man, its founder’s Swiss surgical simulator company, for ₹260 crore, payable entirely in shares. This strategic move aims to propel Maverick’s growth, expand its technological capabilities, and solidify its position in a rapidly expanding sector.
The imperative for advanced medical training is clear: ensuring practitioners gain proficiency in a risk-free environment. Maverick Simulation Solutions addresses this critical need, offering state-of-the-art training solutions. This week, shareholders are set to vote on two pivotal proposals: the ₹125 crore fundraising initiative and the ₹260 crore acquisition of Voxel-Man, structured as a full share-based transaction.
Maverick’s Core Business and Growth Trajectory
Maverick specializes in developing highly sophisticated medical simulation mannequins. These life-sized, interactive models emulate physiological responses—breathing, pulse, and emergent conditions—enabling doctors and nurses to practice critical procedures such as CPR, injections, and emergency interventions without patient risk. Maverick supplies these systems and comprehensive simulation laboratories to over 100 institutions, including premier medical colleges and hospitals like AIIMS and the IITs.
The company has experienced robust growth, with revenue escalating from ₹14 crore in FY24 to ₹136 crore in FY25, achieving a profit of approximately ₹48 crore. However, a substantial portion of this revenue, around ₹105 crore, remained in receivables at year-end, highlighting a working capital need that the fresh capital aims to address.
The Capital Infusion
Maverick is securing ₹125.5 crore through the issuance of compulsorily convertible preference shares (CCPS) at a price of ₹3,118 per share. These CCPS are designed to convert into equity shares at a later date, providing investors with certain protective provisions. The capital is earmarked for strategic growth initiatives, new product development, and potential future acquisitions. Concurrently, a ₹13 crore loan from founder Anuj Chahal will be converted into equity, and the company is seeking authorization to borrow up to ₹800 crore.
Key Investors in the Fundraise
| Investor | Description | Amount (₹ crore) | Stake After Deal |
|---|---|---|---|
| Paragon Partners Growth Fund II | Mumbai-based private equity fund, co-founded by Siddharth Parekh | 75.0 | 3.90% |
| VantEdge Partners LLP | Delhi-based company, limited public information | 38.5 | 2.00% |
| Inviga Healthcare Fund I | Bengaluru-based healthcare fund, founded by HCG founder Dr B.S. Ajaikumar | 12.0 | 0.62% |
Paragon Partners emerges as the lead investor. The participation of Inviga Healthcare Fund, a specialized healthcare-focused fund, further validates Maverick’s market position and potential within the medical training sector.
The Voxel-Man Acquisition
Maverick is acquiring Voxel-Man GmbH, a Swiss company, for ₹260 crore. This transaction is entirely share-based, with Maverick issuing new shares to Voxel-Man’s sole owner, Anuj Chahal, who is also Maverick’s promoter, founder, and a director. Given Mr. Chahal’s dual role, this transaction is formally presented to shareholders as a related-party transaction.
The acquisition will be executed in two phases: an initial purchase of 2% of Voxel-Man for ₹5.2 crore, followed by the acquisition of the remaining 98% for ₹254.8 crore by October 2027. A key provision protects the new Series B investors from dilution; their stake will be topped up with additional shares if required, a protection not extended to other existing shareholders.
Strategic Rationale for Voxel-Man Acquisition
Founded in 1984 as a research initiative in Hamburg, Germany, Voxel-Man specializes in advanced virtual surgery simulators for complex procedures in ear, sinus, dental surgery, and ultrasound. Its systems offer haptic feedback, allowing trainees to experience realistic sensations during virtual operations.
The acquisition offers significant strategic synergies:
- Comprehensive Portfolio: Maverick’s expertise in cost-effective physical simulators manufactured in India complements Voxel-Man’s high-end virtual surgery technology and established global brand.
- Expanded Market Access: The combined entity can offer a more complete range of simulation lab solutions globally. Voxel-Man gains immediate access to India’s rapidly expanding medical education market.
- Technological Advancement: Maverick integrates advanced virtual reality and haptic technologies, enhancing its product offering and competitive edge.
Valuation and Shareholding Impact
To determine Maverick’s valuation, the fully diluted share count is multiplied by the Series B investor price of ₹3,118 per share.
Share Count Evolution
| Stage | Shares Added | Total Shares (Approx.) | Promoter % (Approx.) | Value at ₹3,118 (Approx.) |
|---|---|---|---|---|
| Before EGM | – | 5,727,952 | 69.45% | ₹1,786 crore |
| Loan Conversion | 41,853 | 5,769,805 | 69.67% | ₹1,799 crore |
| Series B Fundraise | 402,496 | 6,172,291* | 65.13% | ₹1,925 crore |
| Voxel-Man Tranche 1 (2%) | 16,677 | 6,188,968 | 65.22% | ₹1,930 crore |
| Voxel-Man Tranche 2 (98%) | 817,190 | 7,006,158 | 69.28% | ₹2,185 crore |
*Note: The total share count increases by approximately 1.28 million shares, representing a 22% expansion. The promoter’s stake initially dilutes post-fundraise but largely restores to around 69% following the full Voxel-Man acquisition. The figures above are approximate and account for a revised Series A CCPS conversion ratio. These calculations do not include the Series B top-up clause for dilution protection.
Valuation Benchmarking
| Metric | Value/Description | Implication/Comparison |
|---|---|---|
| Series B Price | ₹3,118 per share | Implies ~40x FY25 profit on a ~₹1,925 crore valuation |
| Unlisted Market Price (Aug–Sep 2026) | ₹2,320–2,375 per share | Series B price represents a 31–34% premium |
| Voxel-Man Acquisition | ₹260 crore (~$30 million) | Revenue not disclosed, making direct comparison challenging |
| Simbionix Acquisition (by Surgical Science, 2021) | $305 million | Approximately 7.4x its revenue (for comparison) |
| CAE Healthcare Sale (to Madison Industries, 2023) | $227 million | A global leader in patient simulators |
The Series B capital raise is being executed at a significant premium to Maverick’s unlisted market price. Post-fundraise, Maverick’s valuation approaches that of established global players in the simulation market, such as CAE Healthcare.
Medical Simulation Sector Growth Drivers
The medical simulation sector is experiencing robust growth, driven by several macro and regulatory factors:
- Expansion of Medical Education: India’s aggressive expansion of medical colleges, with 816 institutions and 1.37 lakh MBBS seats in 2025-26, and a projected addition of 75,000 more seats, creates a continuous demand pipeline for simulation solutions. Each new institution represents a potential Maverick client.
- Mandatory Skills Laboratories: Regulatory bodies like the National Medical Commission (NMC) now mandate that all medical colleges establish skills laboratories equipped with mannequins and trainers, embedding demand into the curriculum.
- Enhanced Patient Safety: Increasing ethical and practical challenges in training on live patients or cadavers underscore the value of simulators, which offer repeatable, risk-free practice environments.
- “Make in India” Initiative: The prevalence of expensive imported high-end simulators creates a significant market opportunity for local manufacturers offering cost-effective alternatives. Globally, the medical simulation market is valued at approximately $3.5 billion, with an annual growth rate of 15%.
Publicly Traded Comparables
Pure-play medical simulation companies are primarily privately held (e.g., Laerdal, Gaumard). Closest publicly listed entities include:
- Surgical Science (Stockholm): The nearest pure-play, specializing in VR surgical simulators.
- Intuitive Surgical (NASDAQ: ISRG): Offers simulators for its da Vinci surgical robots.
- VirTra (NASDAQ: VTSI): Focuses on simulation for law enforcement and military training.
- CAE (NYSE: CAE): A giant in flight simulation, which divested its healthcare division in 2023.
Shareholder Considerations
Maverick Simulation Solutions operates within an attractive and high-demand sector. However, the comprehensive shareholder meeting encompasses multiple significant actions: the founder’s loan conversion, the acquisition of a founder-owned entity (Voxel-Man) for shares, and the resultant adjustment of the founder’s stake to approximately 68%. While new investors are protected from dilution, other existing shareholders do not receive similar safeguards.
Before casting their votes, shareholders are advised to seek full transparency regarding the independent valuation report for Voxel-Man and detailed financial disclosures, including Voxel-Man’s revenue and profit figures.
Latest Price : https://mrgaga.in/unlisted-share
